Presentation is loading. Please wait.

Presentation is loading. Please wait.

Benchmarking scatterplot for non-ICU units.

Published bySybil Hamilton Modified over 5 years ago

Similar presentations

Presentation on theme: "Benchmarking scatterplot for non-ICU units."— Presentation transcript:

1 Benchmarking scatterplot for non-ICU units.
Benchmarking scatterplot for non-ICU units. Each hospital is depicted by its number and its position, defined by its performance for glycemic control (day-weighted mean glucose) on the y-axis, and hypoglycemia rates per patient-day on the x-axis. Quartiles of performance are depicted by the broken lines, with the top performers in the left lower quadrant attaining the best quartile of performance for both hyper- and hypoglycemia rates. The red color highlights an individual hospital's performance. BG, blood glucose. Greg Maynard et al. Diabetes Spectr 2014;27: ©2014 by American Diabetes Association

Download ppt "Benchmarking scatterplot for non-ICU units."

Similar presentations

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Components of a CGM record over a 3

Components of a CGM record over a 3
Modulation of the intensiveness of glucose lowering in type 2 diabetes

Modulation of the intensiveness of glucose lowering in type 2 diabetes
Volume 70, Issue 8, Pages (October 2006)

Volume 70, Issue 8, Pages (October 2006)
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
George Dailey, MD  Mayo Clinic Proceedings 

George Dailey, MD  Mayo Clinic Proceedings 
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Practical diagram of typical insulin dose requirements for type 1, type 2, and other forms of diabetes mellitus. Practical diagram of typical insulin dose.

Practical diagram of typical insulin dose requirements for type 1, type 2, and other forms of diabetes mellitus. Practical diagram of typical insulin dose.
Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making.

Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making.
Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.

Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.
Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.
Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.
Severe hypoglycemia after initiation of anti–tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2.

Severe hypoglycemia after initiation of anti–tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2.
PWD confidence with key diabetes management activities.

PWD confidence with key diabetes management activities.
PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Similar presentations

Ads by Google